Setidegrasib + Oxaliplatin + Leucovorin + Irinotecan + fluorouracil + liposomal irinotecan + Placebo
Phase 3RecruitingInterest: 47/100
47
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Pancreatic Cancer
Conditions
Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma
Trial Timeline
Feb 17, 2026 → Aug 31, 2029
NCT ID
NCT07409272About Setidegrasib + Oxaliplatin + Leucovorin + Irinotecan + fluorouracil + liposomal irinotecan + Placebo
Setidegrasib + Oxaliplatin + Leucovorin + Irinotecan + fluorouracil + liposomal irinotecan + Placebo is a phase 3 stage product being developed by Astellas Pharma for Pancreatic Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07409272. Target conditions include Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma.
What happened to similar drugs?
9 of 20 similar drugs in Pancreatic Cancer were approved
Approved (9) Terminated (5) Active (10)
Hype Score Breakdown
Clinical
17
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07409272 | Phase 3 | Recruiting |
Competing Products
20 competing products in Pancreatic Cancer